Trial Profile
AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer (PaTK01).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Advantagene; Candel Therapeutics
- 28 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
- 24 Feb 2015 Planned End Date changed from 1 May 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 14 Jan 2013 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.